inotuzumab
pfizer,ucb pharmaceuticals
['leusm', 'inotuzumab']
dr. stelljes presents data from gmall-initial1 study (pts age 55+ w/ ph-neg b-all) using 3 cycles of inotuzumab (ino) followed by consolidation. 43 pts, 12 age 70+ -&gt; cr/cri 100% after 2 cycles, 74% mrd-neg after 3 cycles. zero early deaths (w/in 6m). (1/2) #ash22 #leusm #allsm 
Leukemia/cell therapy doc & AYA Leukemia Program Leader at @MSKCancerCenter w/ special interest in ALL. Indie rock & Boston sports fan. Opinions=my own.??????